AlphaCrest Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-35,044
| Closed | -$573K | – | 13 |
|
|
2022
Q3 | $573K | Buy |
35,044
+24,258
| +225% | +$397K | 0.03% | 918 |
|
|
2022
Q2 | $152K | Sell |
10,786
-40,760
| -79% | -$574K | 0.01% | 1220 |
|
|
2022
Q1 | $1.25M | Buy |
51,546
+34,143
| +196% | +$827K | 0.07% | 445 |
|
|
2021
Q4 | $406K | Sell |
17,403
-49,276
| -74% | -$1.15M | 0.02% | 1168 |
|
|
2021
Q3 | $1.11M | Buy |
66,679
+11,874
| +22% | +$197K | 0.06% | 569 |
|
|
2021
Q2 | $1.34M | Buy |
54,805
+13,601
| +33% | +$332K | 0.06% | 524 |
|
|
2021
Q1 | $1.06M | Buy |
41,204
+31,960
| +346% | +$825K | 0.06% | 474 |
|
|
2020
Q4 | $494K | Buy |
+9,244
| New | +$494K | 0.04% | 657 |
|
|
2020
Q3 | – | Sell |
-6,233
| Closed | -$302K | – | 1076 |
|
|
2020
Q2 | $302K | Sell |
6,233
-16,838
| -73% | -$816K | 0.05% | 625 |
|
|
2020
Q1 | $975K | Buy |
23,071
+12,430
| +117% | +$525K | 0.12% | 287 |
|
|
2019
Q4 | $455K | Buy |
10,641
+2,945
| +38% | +$126K | 0.04% | 846 |
|
|
2019
Q3 | $277K | Buy |
+7,696
| New | +$277K | 0.02% | 1118 |
|